TXG 10x Genomics, Inc.
$78.02▲ +6.94%
Healthcare
Other
After hours
$78.99▲ +1.24%
Oct 27, 5:35 PM ET
Volume 2.13M
Avg Volume (10D) 3.22M
Key Metrics & Fundamentals
Market Cap
$10.17B
P/E Ratio
–
Div Yield
0.00%
52W Range
12.34 - 102.81
% vs 50 MA
6.73%
% vs 200 MA
96.51%
RSI-14
53.9
MACD Histogram
-0.6400
Beta (1Y vs SPY)
2.25
Free Cash Flow
$15.39M
Gross Rev
$151.04M
Gross Profit
$112.50M
EBITDA
-$10.37M
COGS
$38.54M
Operating Exp
$135.45M
Operating Income
-$22.96M
EBIT
-$22.96M
Pretax Income
-$18.65M
Net Income
-$17.93M
EPS (Diluted)
-0.14
Price & Volume History
Loading chart…
Recent News
10x Genomics to Participate in the 2026 Jefferies Global Healthcare Conference
PR Newswire · Oct 27, 2026 4:05 PM ET
1 unprofitable stock with exciting potential and 2 that underwhelm
StockStory · Oct 23, 2026 2:40 PM ET
Stephens Downgrades 10x Genomics to Equal Weight From Overweight, $65 Price Target
MT Newswires · Oct 23, 2026 9:33 AM ET
3 Healthcare Stocks That Concern Us
StockStory · Oct 19, 2026 9:28 AM ET
Cathie Wood-Led Ark Invest's Biggest Q3 Winners And Losers — PLTR, NVDA, TXG Led While TSLA, RKLB Dragged
Stocktwits · Oct 17, 2026 4:29 AM ET
10x Genomics (TXG) Stock Fair Value Rises After Analysts Back AI And Atera Demand
Simply Wall St. · Oct 16, 2026 7:20 AM ET
3 Reasons to Sell TXG and 1 Stock to Buy Instead
StockStory · Oct 15, 2026 9:52 AM ET
10x Genomics to Report Third Quarter 2026 Financial Results on November 5, 2026
PR Newswire · Oct 13, 2026 4:05 PM ET
Why Are 10x Genomics (TXG) Shares Soaring Today
StockStory · Oct 9, 2026 8:27 PM ET
BofA Securities Adjusts 10x Genomics Price Target to $80 From $50
MT Newswires · Oct 9, 2026 8:09 AM ET
Financial Overview - Income Statement
Quarterly
Jun 2026
See TXG's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.